Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 274 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Foodie Friday: Couscous Salad August 13, 2021 ΣΤΑΤΙΣΤΙΚΑ January 18, 2019 Seeing a Promising Future for Progress against Childhood Cancer September 16, 2021 Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds July 22, 2019 Load more HOT NEWS A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... ¿Ahora qué? 10 maneras de adaptarse a la vida cotidiana después... 105-Year-Old Woman Sets Record For 100-Meter Dash Michelle Mitchell: Cancer is a fixable problem
